the aid library

LIST OPTIONS

Filter

994

Sort by:

Direction:

Download (133)

View PDF (196)

Female genital mutilation: the prevention and the management of the health complications

World Health Organization (WHO) (2001) C_WHO

Intended for use primarily by those responsible for developing policies and directing the working practices of nurses, midwives and other frontline health-care providers, these guidelines aim to promote and strengthen the case against the medicalization of female genital mutilation and support and p... more

Download (586)

View PDF (1320)

Management of severe malnutrition: a manual for physicians and other senior health workers

World Health Organization WHO (1999) C_WHO

This manual provides practical guidelines for the management of children with severe malnutrition. It seeks to promote the best available therapy so as to reduce the risk of death, shorten the length of time spent in hospital, and facilitate rehabilitation and full recovery. Emphasis is given to the... more

Download (29)

View PDF (25)

Beyond diagnosis and treatment The social protection landscape for people affected by TB in the WHO South-East Asia Region, 2024

World Health Organization WHO (2024) C_WHO

The social protection landscape for people affected by TB in the WHO South-East Asia Region

Download (64)

View PDF (73)

Kenya National Guidelines for Cardiovascular Diseases Management

Ministry of Health Kenya Republic of Kenya (2018) CC

The Kenya Health Policy 2014-2030 aims at attaining the highest possible standard of health in a manner responsive to the health needs of our population. One of the major policy directions towards realizing the intentions of this policy is to halt and reverse the rising burden of non-communicable d... more

Download (51)

View PDF (34)

Risk communication and community engagement readiness and response toolkit: zika virus

World Health Organisation (WHO) (2024) C_WHO

Toolkit regarding Zika Virus

Download (624)

View PDF (1080)

Cervical Cancer Prevention and Control Policy (South Africa)

Dept. of Health, Republic of South Africa (2021) C1

Cervical cancer, along with maternal deaths, has been identified as a national priority in South Africa as well as other Sub-Saharan African countries. Cervical cancer is the second most common cancer among women in South Africa, after breast cancer. Due to limited access to prevention, early dia... more

Download (271)

View PDF (365)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (132)

View PDF (204)

Considerations and Principles for Shielding People at High Risk of Severe Outcomes from COVID-19

Social Science in Humanitarian Action (2020) CC

This brief considers the rationale for shielding individuals at high risk of severe disease or death from COVID-19 in low- and middleincome countries. It provides an overview of proposed approaches to shielding, discusses the categories of individuals who may be identified for shielding, and outline... more

Download (165)

View PDF (318)

Vector-borne diseases: a handbook for pharmacists - Disease prevention, control, management and treatment

Gromek K., Hung M., Montero N. et al International Pharmaceutical Federation FIP (2020) C2

The Pharmaceutical Forum of the Americas (PFA) has previously published guidelines and organised campaigns for community pharmacists on the prevention, detection and control of arbovirus infections in 2018 with a grant from the FIP Foundation for Pharmacy Education and Research. Building on that exp... more

Download (99)

View PDF (479)

The global burden of chromoblastomycosis

Santos, D.; Pedrozo e Silva de Azevedo, C.; Aparecida Vincent, V. et al. (2021) CC

Chromoblastomycosis (CBM), represents one of the primary implantation mycoses caused by melanized fungi widely found in nature. It is characterized as a Neglected Tropical Disease (NTD) and mainly affects populations living in poverty with significant morbidity, including stigma and discrimination.

Download (108)

View PDF (412)

Laboratory techniques in rabies

Rupprecht, C.; Fooks, A,; Abela-Ridder, B. World Health Organization WHO (2018) C_WHO

Rabies has an enormous impact on both agriculture and conservation biology, but its greatest burden is undeniably on public health. As such, routine methods for rapid risk assessment after human exposures to rabies as well as applications for laboratory-based surveillance, production of biologicals ... more

Download (1357)

View PDF (3264)

Infection Control Assessment Tool: A Standardized Approach for Improving Hospital Infection Control Practices

South Africa's Dept. of Health; USAID; SIAPS (2010) C1

The ICAT is a simple and practical approach for assessing the adequacy of existing infection prevention and control practices and provides specific recommendations for improving practices and monitoring their effectiveness over time

Download (115)

View PDF (895)

Surveillance, prevention and control of leishmaniases in the European Union and its neighbouring countries

European Centre for disease prevention and control (ECDC) European Centre for disease prevention and control (ECDC) (2022) C_CDC

This technical report presents the epidemiology of human and animal leishmaniases in the EU and its neighbouring countries and concludes that the disease remains widespread and underreported in many countries of southern Europe, northern Africa, and the Middle East and that there is a need to improv... more

Download (89)

View PDF (398)

Breaking the silence an Opportunity for Patients with Chagas Disease

Moriana, S.; Oritz, G.; Fanjul, G. Chagas Coalition (2016) CC

Not long ago, on the occasion of the 100th anniversary of the discovery of Chagas disease, several campaigns denounced the scant progress has been made in diffrent spheres- medical, scientific and politcal- but major challanges still remain. This is an appropriate time to celebrate what has been ach... more

Download (139)

View PDF (174)

Antimicrobial Resistance in Food-Animal Production INDIA OVERVIEW

Action on Anitbiotic Resistance (ReAct) (2018) C2

Indian markets caused a stir across the country.1 According to the Centre for Science and the Environment (CSE), a respected New Delhi-based NGO, most honey brands sold in India contained varying amounts of antibiotics. Their consumption over time could induce resistance to antibiotics, putting p... more

Download (158)

View PDF (240)

Australian guidelines for the clinical care of people with MPX

Australian National Clinical Evidence Taskforce (2022) C1

Nov 11, 2022

Download (385)

View PDF (259)

Libyan Essential Medicines List - 1st Edition

Government of Libya (2022) C1

The pharmaceutical sector of any nation is responsible for providing society with quality medicines and other pharmaceutical services. According to the World Health Organization (WHO), Pharmaceuticals may constitute as much as 40% of the national health budget in developing countries, yet portions o... more

Download (154)

View PDF (182)

Responding to outbreaks of antimicrobial-resistant pathogens in health-care facilities: guidance for the Western Pacific region

World Health Organization WHO (2022) C_WHO

Responding to Outbreaks of Antimicrobial-resistant Pathogens in Health-care Facilities: Guidance for the Western Pacific Region is developed following requests from Member States in the Western Pacific Region for additional information and support in managing AMR outbreaks. It aims to provide: a ste... more

Download (182)

View PDF (162)

WHO operational handbook on tuberculosis: module 3: diagnosis: tests for tuberculosis infection

World Health Organization WHO (2022) C_WHO

Three classess of tests are now recommended in the latest consolidated guideles on tests for tuberculosis infection. It includes for the first-time a new class of Mycobacterium tuberculosis antigen-based skin tests (TBSTs), and the two existing classes of tests: the tuberculin skin test (TST) and t... more

Download (139)

View PDF (155)

Framework for collaborative action on tuberculosis and comorbidities

World Health Organization WHO (2022) C_WHO

Addressing comorbidities and risk factors for TB is a crucial component of Pillar one of the End TB Strategy, which focuses on integrated patient-centred care and prevention, including action on TB and comorbidities. The Framework for collaborative action on TB and comorbidities aims to support coun... more